OGA and neoplasm: Key tool compounds include OGT inhibitors (e.g., OSMI‐1, OSMI‐4) and OGA inhibitors (e.g., Thiamet‐G, MK‐8719), which have provided proof‐of‐concept that pharmacologically modulating O‐GlcNAcylation can alter tumour progression and autophagic flux.